113 related articles for article (PubMed ID: 12419382)
21. Environmentally benign synthesis of unsymmetrical ureas and their evaluation as potential HIV-1 protease inhibitors via a computational approach.
Lotha TN; Richa K; Sorhie V; Ketiyala ; Nakro V; Imkongyanger ; Ritse V; Rudithongru L; Namsa ND; Jamir L
Mol Divers; 2024 Apr; 28(2):749-763. PubMed ID: 36788191
[TBL] [Abstract][Full Text] [Related]
22. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 protease inhibitors: a comparative QSAR analysis.
Kurup A; Mekapati SB; Garg R; Hansch C
Curr Med Chem; 2003 Sep; 10(17):1679-88. PubMed ID: 12871116
[TBL] [Abstract][Full Text] [Related]
24. Novel lopinavir analogues incorporating heterocyclic replacements of six-member cyclic urea--synthesis and structure-activity relationships.
Sham HL; Betebenner DA; Rosenbrook W; Herrin T; Saldivar A; Vasavanonda S; Plattner JJ; Norbeck DW
Bioorg Med Chem Lett; 2004 May; 14(10):2643-5. PubMed ID: 15109669
[TBL] [Abstract][Full Text] [Related]
25. The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
Patel M; Bacheler LT; Rayner MM; Cordova BC; Klabe RM; Erickson-Viitanen S; Seitz SP
Bioorg Med Chem Lett; 1998 Apr; 8(7):823-8. PubMed ID: 9871548
[TBL] [Abstract][Full Text] [Related]
26. A quantitative structure-activity relationship study on some HIV-1 protease inhibitors using molecular connectivity index.
Gayathri P; Pande V; Sivakumar R; Gupta SP
Bioorg Med Chem; 2001 Nov; 9(11):3059-63. PubMed ID: 11597490
[TBL] [Abstract][Full Text] [Related]
27. Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups.
Rodgers JD; Johnson BL; Wang H; Erickson-Viitanen S; Klabe RM; Bacheler L; Cordova BC; Chang CH
Bioorg Med Chem Lett; 1998 Apr; 8(7):715-20. PubMed ID: 9871528
[TBL] [Abstract][Full Text] [Related]
28. QSAR studies on HIV-1 protease inhibitors using non-linearly transformed descriptors.
Saranya N; Selvaraj S
Curr Comput Aided Drug Des; 2012 Mar; 8(1):10-49. PubMed ID: 21999608
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and structure-activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir).
Sham HL; Betebenner DA; Chen X; Saldivar A; Vasavanonda S; Kempf DJ; Plattner JJ; Norbeck DW
Bioorg Med Chem Lett; 2002 Apr; 12(8):1185-7. PubMed ID: 11934584
[TBL] [Abstract][Full Text] [Related]
30. Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors.
Nugiel DA; Jacobs K; Kaltenbach RF; Worley T; Patel M; Meyer DT; Jadhav PK; De Lucca GV; Smyser TE; Klabe RM; Bacheler LT; Rayner MM; Seitz SP
J Med Chem; 1996 May; 39(11):2156-69. PubMed ID: 8667359
[TBL] [Abstract][Full Text] [Related]
31. Receptor-independent 4D-QSAR analysis of a set of norstatine derived inhibitors of HIV-1 protease.
Senese CL; Hopfinger AJ
J Chem Inf Comput Sci; 2003; 43(4):1297-307. PubMed ID: 12870923
[TBL] [Abstract][Full Text] [Related]
32. Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents.
Patel M; Rodgers JD; McHugh RJ; Johnson BL; Cordova BC; Klabe RM; Bacheler LT; Erickson-Viitanen S; Ko SS
Bioorg Med Chem Lett; 1999 Nov; 9(22):3217-20. PubMed ID: 10576691
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of conceptual DFT descriptors and docking scores on the QSAR models of HIV protease inhibitors.
Srivastava HK; Choudhury C; Sastry GN
Med Chem; 2012 Sep; 8(5):811-25. PubMed ID: 22741804
[TBL] [Abstract][Full Text] [Related]
34. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.
Hultén J; Bonham NM; Nillroth U; Hansson T; Zuccarello G; Bouzide A; Aqvist J; Classon B; Danielson UH; Karlén A; Kvarnström I; Samuelsson B; Hallberg A
J Med Chem; 1997 Mar; 40(6):885-97. PubMed ID: 9083477
[TBL] [Abstract][Full Text] [Related]
35. Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities.
Ala PJ; Huston EE; Klabe RM; Jadhav PK; Lam PY; Chang CH
Biochemistry; 1998 Oct; 37(43):15042-9. PubMed ID: 9790666
[TBL] [Abstract][Full Text] [Related]
36. Comparative molecular field analysis (CoMFA), topomer CoMFA, and hologram QSAR studies on a series of novel HIV-1 protease inhibitors.
Heidari A; Fatemi MH
Chem Biol Drug Des; 2017 Jun; 89(6):918-931. PubMed ID: 27933723
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and Biological Evaluation of 3,9-Dioxatetraasteranes as C
Li P; Wang S; Wang H; Yan H
Biol Pharm Bull; 2019; 42(2):261-267. PubMed ID: 30713256
[TBL] [Abstract][Full Text] [Related]
38. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.
Lam PY; Jadhav PK; Eyermann CJ; Hodge CN; Ru Y; Bacheler LT; Meek JL; Otto MJ; Rayner MM; Wong YN
Science; 1994 Jan; 263(5145):380-4. PubMed ID: 8278812
[TBL] [Abstract][Full Text] [Related]
39. Validated predictive QSAR modeling of N-aryl-oxazolidinone-5-carboxamides for anti-HIV protease activity.
Halder AK; Jha T
Bioorg Med Chem Lett; 2010 Oct; 20(20):6082-7. PubMed ID: 20832304
[TBL] [Abstract][Full Text] [Related]
40. Revealing interaction mode between HIV-1 protease and mannitol analog inhibitor.
Yan GW; Chen Y; Li Y; Chen HF
Chem Biol Drug Des; 2012 Jun; 79(6):916-25. PubMed ID: 22296911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
